NASDAQ:STRO - Sutro Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.50
  • Forecasted Upside: 56.33 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$18.87
▲ +0.12 (0.64%)

This chart shows the closing price for STRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sutro Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STRO

Analyst Price Target is $29.50
▲ +56.33% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $29.50, with a high forecast of $37.00 and a low forecast of $22.00. The average price target represents a 56.33% upside from the last price of $18.87.

This chart shows the closing price for STRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Sutro Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2021Wells Fargo & CompanyReiterated RatingBuy$30.00Low
6/22/2021JMP SecuritiesReiterated RatingBuy$28.00High
6/18/2021HC WainwrightInitiated CoverageBuy$35.00High
1/28/2021TruistBoost Price Target$24.00 ➝ $37.00Medium
12/2/2020Stifel NicolausInitiated CoverageBuy$25.00Low
11/6/2020Piper SandlerBoost Price TargetOverweight$20.00 ➝ $22.00Low
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$21.00High
7/16/2020Wells Fargo & CompanyInitiated CoverageOverweight$18.00High
5/18/2020Piper SandlerLower Price Target$23.00 ➝ $20.00Medium
5/13/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $17.00Low
5/12/2020B. RileyDowngradeHoldLow
3/17/2020HC WainwrightReiterated RatingBuy$18.00High
3/16/2020CowenReiterated RatingBuyHigh
1/13/2020SunTrust BanksInitiated CoverageBuy$18.00Low
10/30/2019WedbushReiterated RatingOutperformMedium
10/21/2019HC WainwrightReiterated RatingBuy$18.00High
10/7/2019BTIG ResearchInitiated CoverageBuy$19.00High
9/5/2019JMP SecuritiesReiterated RatingMarket Outperform$16.00Medium
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$22.00High
6/24/2019HC WainwrightSet Price TargetBuy$18.00Low
6/16/2019CowenReiterated RatingBuyLow
5/17/2019HC WainwrightSet Price TargetBuy$18.00Low
5/16/2019CowenReiterated RatingBuyLow
5/7/2019HC WainwrightReiterated RatingBuy$18.00High
4/29/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
3/4/2019WedbushBoost Price TargetOutperform$20.00 ➝ $22.00Low
10/22/2018CowenInitiated CoverageOutperformMedium
10/22/2018WedbushInitiated CoverageOutperform ➝ Outperform$20.00Medium
10/22/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$28.00Medium
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00Medium
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
8/23/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2021

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sutro Biopharma logo
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $18.87
Low: $18.29
High: $19.00

50 Day Range

MA: $19.69
Low: $18.36
High: $22.38

52 Week Range

Now: $18.87
Low: $11.99
High: $28.30

Volume

2,412 shs

Average Volume

404,596 shs

Market Capitalization

$870.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Sutro Biopharma?

The following Wall Street research analysts have issued stock ratings on Sutro Biopharma in the last twelve months: HC Wainwright, JMP Securities, Piper Sandler, Stifel Nicolaus, TheStreet, Truist, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for STRO.

What is the current price target for Sutro Biopharma?

6 Wall Street analysts have set twelve-month price targets for Sutro Biopharma in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 56.3%. Truist has the highest price target set, predicting STRO will reach $37.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $22.00 for Sutro Biopharma in the next year.
View the latest price targets for STRO.

What is the current consensus analyst rating for Sutro Biopharma?

Sutro Biopharma currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STRO will outperform the market and that investors should add to their positions of Sutro Biopharma.
View the latest ratings for STRO.

How do I contact Sutro Biopharma's investor relations team?

Sutro Biopharma's physical mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company's listed phone number is (650) 392-8412 and its investor relations email address is [email protected] The official website for Sutro Biopharma is www.sutrobio.com.